Skip to Content
Merck
  • Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.

Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.

The Journal of antimicrobial chemotherapy (2014-08-21)
Gita N Shankar, Carsten Alt
ABSTRACT

Over-the-counter access to an inexpensive, effective topical microbicide could reduce the transmission of HIV and would increase women's control over their health and eliminate the need to obtain their partners' consent for prophylaxis. Chronic infection with herpes simplex virus 2 (HSV-2), also known as human herpes virus 2, has been shown to facilitate HIV infection and speed the progression to immunodeficiency disease. Our objective is to develop a drug formulation that protects against both HSV-2 and HIV infection and adheres to the vaginal surface with extended residence time. We developed a formulation using two approved antiviral active pharmaceutical ingredients, aciclovir and tenofovir, in a novel bioadhesive vaginal delivery platform (designated SR-2P) composed of two polymers, poloxamer 407 NF (Pluronic(®) F-127) and polycarbophil USP (Noveon(®) AA-1). The efficacy of the formulation to protect from HSV-2 infection was tested in vitro and in vivo. In addition to its efficacy, it is essential for a successful microbicide to be non-irritating to the vaginal mucosa. We therefore tested our SR-2P platform gel in the FDA gold-standard microbicide safety model in rabbits and also in a rat vaginal irritation model. Our studies indicated that SR-2P containing 1% aciclovir and 5% tenofovir protects (i) Vero cells from HSV-2 infection in vitro and (ii) mice from HSV-2 infection in vivo. Our results further demonstrated that SR-2P was not irritating in either vaginal irritation model. We conclude that SR-2P containing aciclovir and tenofovir may be a suitable candidate microbicide to protect humans from vaginal HSV-2 infection.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
D-(−)-Fructose, BioUltra, ≥99.0% (HPLC)
Sigma-Aldrich
Acetic acid, ≥99.5%, FCC, FG
Sigma-Aldrich
Urea-12C, 99.9 atom % 12C
Sigma-Aldrich
Lactic acid, 85%, FCC
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
D-(−)-Fructose, ≥99% (HPLC)
Sigma-Aldrich
D-(−)-Fructose, ≥99% (HPLC), BioXtra
Sigma-Aldrich
D-(−)-Fructose, 98.0-102.0% dry basis, meets USP testing specifications
Supelco
D-(−)-Fructose, analytical standard, analytical standard for fructose assay kit, for use with enzymatic assay kit FA20
Sigma-Aldrich
Magnesium chloride solution, for molecular biology, 1.00 M±0.01 M
Sigma-Aldrich
Magnesium chloride solution, PCR Reagent, 25 mM MgCI2 solution for PCR
Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
Potassium chloride, for molecular biology, ≥99.0%
Sigma-Aldrich
Acetic acid-12C2, 99.9 atom % 12C
Supelco
Methylparaben, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Fructose, Pharmaceutical Secondary Standard; Certified Reference Material
Millipore
Urea solution, suitable for microbiology, 40% in H2O
Supelco
Lactic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Lactic acid, meets USP testing specifications
Supelco
Acetic acid, analytical standard
Sigma-Aldrich
Potassium chloride, ACS reagent, 99.0-100.5%
Sigma-Aldrich
Acetic acid, natural, ≥99.5%, FG
Sigma-Aldrich
Lactic acid, natural, ≥85%
Supelco
Potassium chloride solution, ~3 M KCl, saturated with silver chloride
Sigma-Aldrich
Potassium chloride, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99%
Supelco
Sodium Citrate, Pharmaceutical Secondary Standard; Certified Reference Material
Methyl parahydroxybenzoate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Acetic acid, glacial, ≥99.99% trace metals basis
Sigma-Aldrich
Acetic acid solution, suitable for HPLC
Sigma-Aldrich
Acetic acid, glacial, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, 99.8-100.5%